Psoriasis over 6 years of follow-up (N=158) | No psoriasis over 6 years of follow-up (N=431) | At 6 years: p value of univariable analysis (N=589) | Over 6 years: linear mixed-effects model: univariable effect estimate (95% CI) (N=708) | |
Key outcomes | ||||
ASDAS-CRP, mean (SD) | 2.2 (0.9) | 2.1 (1.0) | 0.36 | 0.03 (−0.07 to 0.13) |
HAQ-AS, mean (SD) (0–3) | 0.60 (0.56) | 0.48 (0.49) | 0.07 | 0.01 (−0.04 to 0.05) |
Other outcomes | ||||
BASDAI, mean (SD) (0–100) | 36.3 (20.2) | 32.8 (21.7) | 0.09 | 0.55 (−1.61 to 2.71) |
BASFI, mean (SD) (0–100) | 25.9 (23.1) | 21.8 (20.6) | 0.13 | −0.52 (−2.61 to 1.56) |
ASQoL, mean (SD) (0–18) | 7.2 (5.4) | 6.4 (5.6) | 0.10 | −0.26 (−0.77 to 0.26) |
SF36 | ||||
Physical Component Summary, mean (SD) (0–100) | 42.7 (9.5) | 43.5 (9.7) | 0.37 | 0.03 (−0.91 to 0.97) |
Mental Component Summary, mean (SD) (0–100) | 43.3 (10.7) | 44.8 (11.4) | 0.07 | −0.13 (−1.29 to 1.04) |
Work loss (days per year), mean (SD) | 20.9 (32.8) | 21.2 (38.5) | 0.70 | |
Tender joint count, mean (SD) (0–53) | 3.4 (7.7) | 2.2 (4.6) | 0.11 | 0.20 (−0.66 to 1.07) |
Swollen joint count, mean (SD) (0–28) | 0.2 (1.3) | 0.1 (0.3) | 0.37 | 0.08 (0.02 to 0.15) |
MASES enthesitis index, mean (SD) (0–13) | 2.2 (3.1) | 2.0 (3.0) | 0.38 | 0.31 (0.004 to 0.62) |
CRP (mg/L), mean (SD) | 5.4 (8.5) | 4.8 (6.7) | 0.71 | 0.81 (−0.22 to 1.84) |
mSASSS*, mean (SD)(0–72) | 1.3 (4.7) | 1.0 (3.0) | 0.85 | 0.23 (0.01 to 0.59) |
Change in mSASSS between baseline and year 5, mean (SD) | 0.42 (2.0) | 0.42 (1.7) | 0.94 | |
Modified New York radiographic criteria during follow-up (local reading), n (%) | 48 (30.4) | 142 (32.9) | 0.62 | OR: 1.38 (0.57 to 3.35) |
NSAIDs intake since last visit, n (%) | 79 (63.7) | 196 (66.4) | 0.67 | OR: 0.92 (0.63 to 1.35) |
Current csDMARDs intake, n (%) | 35 (44.3) | 52 (34.9) | 0.21 | OR: 1.38 (0.70 to 2.74) |
Methotrexate intake at least once during follow-up, n (%) | 37 (25.5) | 42 (11.8) | <0.001 OR: 2.57 (1.57; 4.21) | OR: 2.05 (0.84 to 5.00) |
bDMARDs intake at least once during follow-up, n (%) | 88 (55.7) | 164 (38.5) | <0.001 OR: 2.01 (1.39; 2.91) | OR: 0.83 (0.38 to 1.81) |
Effect estimates are beta unless otherwise indicated.
Values in bold are significant values at p-value <0.05 in univariable analyses at 6 years and over 6 years.
*Last assessment at year 5.
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-C reactive protein; ASQoL, Ankylosing Spondylitis Quality of Life Scale; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARDs, biological DMARDs; csDMARDs, conventional synthetic disease modifying anti-rheumatic drugs ; HAQ-AS, Health Assessment Questionnaire for axSpA; MASES, Maastricht Ankylosing Spondylitis Enthesis score; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; SF-36, Short Form 36 Health Survey.